batracylin

Batracylin is an investigational anticancer agent that functions as a dual inhibitor of DNA topoisomerases I and II. It was isolated in 1978 by the National Cancer Institute (NCI) during a search for new anticancer drugs. The compound has shown promising activity against solid tumors and Adriamycin-resistant leukemia in preclinical studies. Its mechanism of action involves inducing DNA damage through topoisomerase inhibition, resulting in DNA-protein cross-links and DNA strand breaks. In clinical development, dose-limiting hemorrhagic cystitis was observed, likely related to the formation of a toxic metabolite, N-acetylbatracylin (NAB).

Other names

8-aminoisoindolo[1,2-b]quinazolin-10(12H)-one8-aminoisoindolo[1,2-b]quinazolin-12(10H)-oneBATdaniquidone